Astellas Pharma is focusing on diversification, with its portfolio spanning cancer, vision loss and menopause treatments. Its Chief Medical Officer, Tadaaki Taniguci, said the company was also expanding its gene therapy output, using acquisitions and licensing to build capability, while in oncology, the firm’s lead drugs include treatments for prostate and bladder cancer. Astellas is also testing a small molecule for treating menopause symptoms.
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
